0001628280-20-017743.txt : 20201223
0001628280-20-017743.hdr.sgml : 20201223
20201223182355
ACCESSION NUMBER: 0001628280-20-017743
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201222
FILED AS OF DATE: 20201223
DATE AS OF CHANGE: 20201223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FLANAGAN JOSEPH GERARD
CENTRAL INDEX KEY: 0001413644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34746
FILM NUMBER: 201413895
MAIL ADDRESS:
STREET 1: C/O NORTEL NETWORKS CORPORATION
STREET 2: 195 THE WEST MALL
CITY: TORONTO
STATE: A6
ZIP: M9C 5K1
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: R1 RCM INC.
CENTRAL INDEX KEY: 0001472595
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT SERVICES [8741]
IRS NUMBER: 020698101
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 401 NORTH MICHIGAN AVENUE
STREET 2: SUITE 2700
CITY: CHICAGO
STATE: IL
ZIP: 60611
BUSINESS PHONE: 312-324-7820
MAIL ADDRESS:
STREET 1: 401 NORTH MICHIGAN AVENUE
STREET 2: SUITE 2700
CITY: CHICAGO
STATE: IL
ZIP: 60611
FORMER COMPANY:
FORMER CONFORMED NAME: Accretive Health, Inc.
DATE OF NAME CHANGE: 20090918
4
1
wf-form4_160876582170195.xml
FORM 4
X0306
4
2020-12-22
0
0001472595
R1 RCM INC.
RCM
0001413644
FLANAGAN JOSEPH GERARD
C/O R1 RCM INC.
401 N. MICHIGAN AVENUE, SUITE 2700
CHICAGO
IL
60611
1
1
0
0
President and CEO
Common Stock
2020-12-22
4
M
0
860538
0
A
1925060
D
Common Stock
2020-12-22
4
M
0
2581614
0
A
4506674
D
Common Stock
2020-12-22
4
F
0
1524875
23.43
D
2981799
D
Performance-Based Restricted Stock Units
2020-12-22
4
M
0
860538
0
D
Common Stock
860538.0
0
D
Performance-Based Restricted Stock Units
2020-12-22
4
M
0
2581614
0
D
Common Stock
2581614.0
0
D
Represents shares of common stock received upon settlement of performance-based restricted stock units ("PBRSUs").
Represents a contingent right to receive the Issuer's common stock.
On February 16, 2018, the reporting person was granted PBRSUs that were previously reported on Table II of Form 4 filed on February 16, 2018. Pursuant to the award agreement, the PBRSUs were subject to both a time-based vesting condition and a performance-based vesting condition based upon an average per share price of the Issuer's common stock as defined in the award agreement, measured at December 22, 2020. At target, the PBRSUs covered 245,868 shares. Because the average price per share at the end of the performance period exceeded the maximum target of $9.00 per share, the reporting person earned the maximum number of shares, or 350% of the target award. The time-based vesting condition was fully satisfied on December 22, 2020.
On December 20, 2017, the reporting person was granted PBRSUs that were previously reported on Table II of Form 4/A filed on January 18, 2018. Pursuant to the award agreement, the PBRSUs were subject to both a time-based vesting condition and a performance-based vesting condition based upon an average per share price of the Issuer's common stock as defined in the award agreement, measured at December 22, 2020. At target, the PBRSUs covered 737,604 shares. Because the average price per share at the end of the performance period exceeded the maximum target of $9.00 per share, the reporting person earned the maximum number of shares, or 350% of the target award. The time-based vesting condition was fully satisfied on December 22, 2020.
/s/ E. Terry Platis, Attorney-in-Fact
2020-12-23